Reapplix confirms new funds raised
Birkerød, Denmark, September 27th, 2016
Reapplix today announced that it has successfully closed a new funding round of €2.7 million. This new funding was provided by the existing investors, SEED Capital Denmark, Novo Seeds and Vækstfonden (The Danish Growth Fund).
The new funding will be used to provide continuing forward momentum to the final stages of pre-revenue value creation through to 2018, when Reapplix intends to raise further growth capital in order to undertake the full commercial launch of its lead product, LeucoPatch®.
Graeme Brookes, CEO at Reapplix, commented on the news:
“Having completed the product development and obtained regulatory clearance in both Europe and USA, we are now awaiting the completion in 2017 of our large scale randomized controlled trial, which will be key to gaining reimbursement. This new funding allows us to continue to invest in clinical evidence and in parallel accelerate our work building commercial proof of principle and extensive user traction in selected markets”
Graeme Brookes, CEO
+45 53 77 74 47
Reapplix is a Danish medtech company, founded in 2008 by Niels Erik Holm and Rasmus Lundquist. Reapplix’s core technology is based on the development of blood-based treatments for patients. The company’s first patented product is LeucoPatch® for the treatment of diabetic foot ulcers. Reapplix is a privately-held company backed by three leading Danish investors, SEED Capital, Novo Seeds and Vækstfonden (The Danish Growth Fund), and has been supported by Markedsmodningsfonden.